{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:41:33Z","timestamp":1760888493312,"version":"3.44.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.bone.2010.10.172","type":"journal-article","created":{"date-parts":[[2010,10,31]],"date-time":"2010-10-31T04:45:29Z","timestamp":1288500329000},"page":"597-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bisphosphonates in phenytoin-induced bone disorder"],"prefix":"10.1016","volume":"48","author":[{"given":"Suruchi","family":"Khanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna K.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Vohora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2010.10.172_bb0005","first-page":"378","article-title":"Osteopathies in antiepileptic long-term therapy (preliminary report)","volume":"116","author":"Kruse","year":"1968","journal-title":"Monatsschr Kinderheilkd"},{"key":"10.1016\/j.bone.2010.10.172_bb0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/bmj.4.5894.695","article-title":"Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial","volume":"4","author":"Christiansen","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.bone.2010.10.172_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjopharm.2010.02.003","article-title":"A review of the effect of anticonvulsant medications on bone mineral density and fracture risk","volume":"8","author":"Lee","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.bone.2010.10.172_bb0020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.drudis.2009.01.004","article-title":"Insights into liaison between antiepileptic drugs and bone","volume":"14","author":"Khanna","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bone.2010.10.172_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2010.10.172_bb0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/0972-2327.56312","article-title":"Status epilepticus","volume":"12","author":"Cherian","year":"2009","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.bone.2010.10.172_bb0035","series-title":"Goodman and Gilman's manual of pharmacology and therapeutics","first-page":"333","article-title":"Pharmacotherapy of the epilepsies","author":"McNamara","year":"2008"},{"issue":"2","key":"10.1016\/j.bone.2010.10.172_bb0040","first-page":"24","article-title":"Epilepsy and bone health in adults","volume":"5","author":"Alison","year":"2004","journal-title":"Epilepsy Beh"},{"key":"10.1016\/j.bone.2010.10.172_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jbmr.5650090507","article-title":"Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs","volume":"9","author":"Valimaki","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1196\/annals.1365.036","article-title":"Bisphosphonates","volume":"1092","author":"Lambrinoudaki","year":"2006","journal-title":"Ann NY Acad Sc"},{"issue":"5","key":"10.1016\/j.bone.2010.10.172_bb0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4065\/81.5.662","article-title":"Diagnosis, screening, prevention, and treatment of osteoporosis","volume":"81","author":"Mauck","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bone.2010.10.172_bb0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.maturitas.2010.01.002","article-title":"Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis","volume":"65","author":"Gallagher","year":"2010","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.bone.2010.10.172_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/BMM:3:1:003","article-title":"Bisphosphonates for osteoporosis prevention and treatment","volume":"3","author":"Jarvis","year":"2005","journal-title":"Clin Rev Bone Miner Metab"},{"key":"10.1016\/j.bone.2010.10.172_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-1211(00)00101-7","article-title":"Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy","volume":"40","author":"Tamura","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-7075-3-36","article-title":"Antiepileptic drugs and bone metabolism","volume":"3","author":"Valsamis","year":"2006","journal-title":"Nutr Metab"},{"key":"10.1016\/j.bone.2010.10.172_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrendo.2009.257","article-title":"Use of antiepileptic drugs implicated in fracture risk","volume":"6","author":"Heath","year":"2010","journal-title":"Nat Rev Endocr"},{"key":"10.1016\/j.bone.2010.10.172_bb0085","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/j.1528-1167.2007.01176.x","article-title":"Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure and metabolism","volume":"48","author":"Nissen-Meyer","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.bone.2010.10.172_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3570549","article-title":"Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice","volume":"7","author":"Kimball","year":"1957","journal-title":"Radiat Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose\u2013effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bone.2010.10.172_bb0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1139\/o76-051","article-title":"Acid phosphatase: androgen dependent markers of rat prostate","volume":"54","author":"Tenniswood","year":"1976","journal-title":"Can J Biochem"},{"key":"10.1016\/j.bone.2010.10.172_bb0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with folin-phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.bone.2010.10.172_bb0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0009-8981(67)90167-2","article-title":"Determination of hydroxyproline","volume":"18","author":"Stegemann","year":"1967","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bone.2010.10.172_bb0115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/jcp.54.5.356","article-title":"Method for the measurement of antioxidant activity in human fluids","volume":"54","author":"Koracevic","year":"2001","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.bone.2010.10.172_bb0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0899-9007(02)00962-0","article-title":"Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats","volume":"19","author":"Onodera","year":"2003","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.bone.2010.10.172_bb0125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jbmr.5650090507","article-title":"Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs","volume":"9","author":"Valimaki","year":"1994","journal-title":"Bone Miner Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000229309","article-title":"Bone disease induced by phenytoin therapy: clinical and experimental study","volume":"62","author":"Moro-Alvarez","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.bone.2010.10.172_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0920-1211(98)00077-1","article-title":"Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study","volume":"33","author":"Kubota","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0140","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1053\/seiz.1999.0301","article-title":"Bone density and antiepileptic drug: a case-controlled study","volume":"8","author":"Stephen","year":"1999","journal-title":"Seizure"},{"key":"10.1016\/j.bone.2010.10.172_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1590\/S0004-27302007000300016","article-title":"Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy","volume":"51","author":"Kulak","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.bone.2010.10.172_bb0150","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2010.10.172_bb0155","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2010.10.172_bb0160","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2010.10.172_bb0165","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bone.2010.10.172_bb0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","article-title":"Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study","volume":"18","author":"Silverman","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.bone.2010.10.172_bb0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1359\/JBMR.0301240","article-title":"Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study","volume":"19","author":"Larsen","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.bone.2010.10.172_bb0185","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.10.172_bb0190","unstructured":"Yoshiaki D. 5,5-diphenyl-2,4-imidazolidinedion induced osteoclastogenesis in codulture system of osteoblasts and bone marrow cells. Hokkaido J Dental Sci 2002;23(1):16\u201322."},{"key":"10.1016\/j.bone.2010.10.172_bb0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","article-title":"A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders","volume":"17","author":"Murakami","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.10.172_bb0200","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0013-4694(78)90186-4","article-title":"The frequency of bone abnormality in patients on anticonvulsant therapy","volume":"45","author":"Jowsey","year":"1978","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.bone.2010.10.172_bb0205","first-page":"119","article-title":"The role of biochemical markers of bone turnover in osteoporosis management in clinical practice","volume":"27","author":"Vasikaran","year":"2006","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.bone.2010.10.172_bb0210","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0009-9120(97)00113-6","article-title":"Biochemical markers of bone metabolism: an overview","volume":"30","author":"Christenson","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2010.10.172_bb0215","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.biomaterials.2003.11.024","article-title":"Osteoblast proliferation and maturation by bisphosphonates","volume":"25","author":"Im","year":"2004","journal-title":"Biomater"},{"issue":"1","key":"10.1016\/j.bone.2010.10.172_bb0220","first-page":"S171","article-title":"Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures","volume":"10","author":"Giuliani","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.10.172_bb0225","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","article-title":"Stimulation of bone formation in vitro and in rodents by statins","volume":"286","author":"Mundy","year":"1999","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bone.2010.10.172_bb0230","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.10.172_bb0235","doi-asserted-by":"crossref","first-page":"11-6S","DOI":"10.1016\/0002-9343(93)90375-Y","article-title":"Biochemical markers of bone turnover. I: theoretical considerations and clinical use in osteoporosis","volume":"95","author":"Delmas","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.bone.2010.10.172_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4158\/EP.2.1.13","article-title":"Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects","volume":"2","author":"Kleerekoper","year":"1996","journal-title":"Endocrin Pract"},{"key":"10.1016\/j.bone.2010.10.172_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00198-005-2035-9","article-title":"The role of collagen in bone strength","volume":"17","author":"Viguet-Carrin","year":"2006","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.bone.2010.10.172_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/8756-3282(95)00426-2","article-title":"Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures","volume":"18","author":"Nishikawa","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.10.172_bb0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.nutr.19.1.217","article-title":"Homocysteine metabolism","volume":"19","author":"Selhub","year":"1999","journal-title":"Ann Rev Nutr"},{"key":"10.1016\/j.bone.2010.10.172_bb0260","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-1211(00)00101-7","article-title":"Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy","volume":"40","author":"Tamura","year":"2000","journal-title":"Epilepsy Res"},{"issue":"7567","key":"10.1016\/j.bone.2010.10.172_bb0265","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(68)92404-5","article-title":"Mechanism of folate deficiency in patients receiving phenytoin","volume":"292","author":"Hoffbrand","year":"1968","journal-title":"Lancet"},{"issue":"7\u20138","key":"10.1016\/j.bone.2010.10.172_bb0270","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/106002809502907-816","article-title":"Phenytoin\u2013folic acid interaction","volume":"29","author":"Lewis","year":"1995","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.bone.2010.10.172_bb0275","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/jn\/127.11.2231","article-title":"Phenytoin-induced depletion of folate in rats originates in liver and involves a mechanism that does not discriminate folate form","volume":"127","author":"Carl","year":"1997","journal-title":"J Nutr"},{"key":"10.1016\/j.bone.2010.10.172_bb0280","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/jn\/113.11.2368","article-title":"The effect of chronic phenytoin treatment on tissue folate concentrations and on the activities of the methyl synthetic enzymes in the rat","volume":"113","author":"Carl","year":"1983","journal-title":"J Nutr"},{"key":"10.1016\/j.bone.2010.10.172_bb0285","first-page":"534","article-title":"Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats","volume":"46","author":"Kapoor","year":"2008","journal-title":"Ind J Exp Biol"},{"key":"10.1016\/j.bone.2010.10.172_bb0290","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa032546","article-title":"Homocysteine level and the risk of osteoporotic fracture","volume":"350","author":"Van Meurs","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.10.172_bb0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2006.10.001","article-title":"Homocysteine and bone loss in epilepsy","volume":"16","author":"Elliott","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.bone.2010.10.172_bb0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1172\/JCI118776","article-title":"The oxidant stress of hyperhomocyst(e)inemia","volume":"98","author":"Loscalzo","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.10.172_bb0305","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1172\/JCI114485","article-title":"Oxygen derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo","volume":"85","author":"Garrett","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.10.172_bb0310","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0304-4165(93)90116-P","article-title":"Participation of oxidative stress in the process of osteoclast differentiation","volume":"1157","author":"Suda","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bone.2010.10.172_bb0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2005.03.133","article-title":"Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing","volume":"331","author":"Raisanen","year":"2005","journal-title":"Biochem Biophy Res Comm"},{"key":"10.1016\/j.bone.2010.10.172_bb0320","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bone.2010.10.172_bb0325","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bone.2007.08.005","article-title":"Bisphosphonate antifracture efficacy","volume":"41","author":"Adami","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.10.172_bb0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2010.10.172_bb0335","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.yebeh.2003.11.028","article-title":"Treatment of anticonvulsant drug-induced bone disease","volume":"5","author":"Drezner","year":"2004","journal-title":"Epilepsy Behav"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210019903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210019903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:38:12Z","timestamp":1757612292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210019903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S8756328210019903"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.10.172","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates in phenytoin-induced bone disorder","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2010.10.172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}